- Home
- MAS vs UTHR Comparison
MAS vs UTHR Comparison
Compare MAS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- UTHR
- Stock Information
- Founded
- MAS 1929
- UTHR 1996
- Country
- MAS United States
- UTHR United States
- Employees
- MAS N/A
- UTHR N/A
- Industry
- MAS Industrial Specialties
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- MAS Industrials
- UTHR Health Care
- Exchange
- MAS Nasdaq
- UTHR Nasdaq
- Market Cap
- MAS 14.5B
- UTHR 13.8B
- IPO Year
- MAS N/A
- UTHR 1999
- Fundamental
- Price
- MAS $73.54
- UTHR $313.13
- Analyst Decision
- MAS Buy
- UTHR Buy
- Analyst Count
- MAS 14
- UTHR 13
- Target Price
- MAS $74.36
- UTHR $382.00
- AVG Volume (30 Days)
- MAS 2.8M
- UTHR 691.8K
- Earning Date
- MAS 07-31-2025
- UTHR 07-30-2025
- Dividend Yield
- MAS 1.69%
- UTHR N/A
- EPS Growth
- MAS N/A
- UTHR 17.94
- EPS
- MAS 3.76
- UTHR 25.63
- Revenue
- MAS $7,663,000,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- MAS N/A
- UTHR $14.37
- Revenue Next Year
- MAS $3.81
- UTHR $6.59
- P/E Ratio
- MAS $19.56
- UTHR $12.22
- Revenue Growth
- MAS N/A
- UTHR 17.62
- 52 Week Low
- MAS $56.55
- UTHR $266.98
- 52 Week High
- MAS $86.70
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- MAS 69.27
- UTHR 61.16
- Support Level
- MAS $68.31
- UTHR $292.34
- Resistance Level
- MAS $74.74
- UTHR $306.00
- Average True Range (ATR)
- MAS 1.83
- UTHR 9.55
- MACD
- MAS 0.49
- UTHR 1.92
- Stochastic Oscillator
- MAS 87.43
- UTHR 97.36
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.